A method of reducing tooth-associated pain includes at least shaping plug product into a shape, identifying a source of tooth-associated pain, and engaging the shaped plug product directly with the source of tooth-associated pain. Some implementations include at least shaping a plug product that is at least partly composed of gum base. Some particular implementations include at least shaping a plug product that is completely composed of gum base. Some other particular implementations include at least shaping a plug product that includes one or more numbing agents. Some alternative implementations, include at least shaping a plug product that is at least partly composed of beeswax. A plug product for reducing tooth-associated pain includes a mixture that includes at least one or more numbing agents, at least one of beeswax or gum base and at least one of stevia, corn starch, glycerin, citric acid, or corn syrup.

Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

The present invention provides a patch for attaching to teeth or a surrounding part of teeth, and the patch can be easily removed by tooth brushing alone.

Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of zicronapine, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of zicronapine; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of zicronapine, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.

The present disclosure relates to a method of preparing a thin film composite layer immobilizing vesicles incorporating a transmembrane protein on a porous substrate membrane, comprising providing an aqueous solution comprising the vesicles and a di-amine or tri-amine compound, covering the surface of a porous support membrane with the aqueous solution, applying a hydrophobic solution comprising an acyl halide compound, and allowing the aqueous solution and the hydrophobic solution to perform an interfacial polymerization reaction to form the thin film composite layer.

A composition for the treatment of wounds includes demineralized bone fibers (DBF) derived from allogeneic or xenogenic cortical bone and/or polymeric fibers made from resorbable and/or non-resorbable polymer, and the composition may also include an oxygen-generating material and/or an oxygen carrier.

The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. The biological tissue adhesive sheet according to an embodiment of the present invention includes a nonwoven fabric made of fibers containing a crosslinked gelatin derivative, and the gelatin derivative is represented by Formula 1: Gltn-NH-L-CHR.sup.1R.sup.2, wherein Gltn represents a gelatin residue, L represents a single bond or a divalent linking group, R.sup.1 and R.sup.2 are each independently a hydrocarbon group having 1 to 20 carbon atoms or a hydrogen atom, and at least one selected from the group consisting of R.sup.1 and R.sup.2 is the hydrocarbon group.

The present invention relates to a composition of vaginal film comprising Lactic acid as active ingredient, optionally prebiotics and pharmaceutically acceptable excipients. The present invention also relates to a composition of organic acid vaginal film comprising Lactic acid as active ingredient, optionally fructooligosaccharides as prebiotic, film forming agents, plasticizers, neutralizing agent, lubricants as pharmaceutically acceptable excipients and preservatives, disintegrating agents, anti-foaming agent, antimicrobial agent, coloring agents, flavouring agents as optional excipients. The present invention also relates to process for the preparation of Lactic acid vaginal film comprising the steps of dissolving/melting, mixing, coating/coating & drying and cutting.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.